Future options for aerosol delivery to children.

Area of Science:

• Pediatric Respiratory Medicine
• Pharmacology and Pharmaceutical Science
• Biomedical Engineering

Background:

• Reliable aerosol delivery to the lungs is crucial for effective pediatric treatment, focusing on lung dose, clinical control, cost, and safety.
• Current drug prescription practices often overlook the device's role in determining the actual lung dose, necessitating a shift towards device-specific prescriptions.
• Understanding factors influencing airway drug delivery, such as nasal inhalation and dead space, is key to optimizing inhaled therapies.

Purpose of the Study:

• To highlight the importance of device selection in aerosol therapy for children.
• To discuss recent advancements in aerosol delivery devices aimed at improving lung dose and patient compliance.
• To advocate for device-specific drug approvals and the development of child-centric inhaler technologies.

Main Methods:

• Review of factors affecting aerosol deposition in the lungs, including device design and material properties.
• Analysis of new technologies like nonelectrostatic spacers, intelligent nebulizers, and automatic dry powder inhaler adapters.
• Evaluation of features designed to enhance usability and effectiveness in pediatric patients, such as face masks and reduced dead space.

Main Results:

• Nonelectrostatic materials in spacers significantly increase lung dose by preventing drug loss due to electrostatic attraction.
• Intelligent nebulizers adapt to a child's breathing pattern, optimizing nebulization during inhalation and reducing waste.
• New devices like the AirPac and tower-shaped spacers offer improved aerosol stability, prolonged residence time, and reduced nasal deposition, enhancing drug delivery in children.

Conclusions:

• Device selection is integral to aerosol drug prescription, requiring clear specifications in drug approval processes.
• Innovations in spacer technology, particularly the use of nonelectrostatic materials and child-friendly designs, are essential for improving lung dose and treatment adherence.
• Future developments should focus on intelligent, adaptive devices that cater to the specific needs and behaviors of pediatric patients to optimize inhaled aerosol therapy.